TrialBlood2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Clare Sun et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
59 papers cite it
this paperpooled ittrialcites it